← Back to search
UNIVERSITY OF CAPE TOWN
CAPE TOWN, 7701
UnclaimedClaim this profile (free)
Subcontracting experience
8 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | A1 5/12/2025
THE SCOPE OF PHARMACOKINETICS-RELATED WORK TO BE UNDERTAKEN BY THE
UNIVERSITY OF CAPE TOWN (SOUTH AFRICA) IN SUPPORT OF TBTC STUDY 39 (€œRADIANT KIDS€Ͽ½) AND FUNDED BY A
SUBAWARD FROM THE MEDICAL UNIVERSITY OF SOUTH CAROLINA. THIS SCOPE OF WORK IS PREDICATED ON THE
AVAILABILITY OF A HIGH LEVEL TRAINEE (E.G. MASTERS OR DOCTORAL TRAINEE) ANTICIPATED TO BE SUPPORT BY A
SEPARATE FUNDING MECHANISM. A21-0192-S003 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541714 Parent award description: TUBERCULOSIS TRIALS AND CONSORTIUM View parent award on USAspending | — | $38,359 | Jun 10, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS
CENTER (IMPAC-TB)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ELISA NEMES WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS- CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, DR. NEMES WILL:
€¢ AS LEADER FOR PROJECT 5, PERFORM IMMUNOLOGICAL CHARACTERIZATION OF REVERTERS (RVRTRS), A COHORT OF HUMANS WHO UNDERGO IGRA REVERSION EITHER SPONTANEOUSLY OR AS A RESULT OF PREVIOUS VACCINATION.
€¢ OPTIMIZE, HARMONIZE, AND APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG CELLS FROM HUMAN COHORTS RECRUITED BY PROJECTS 3-5 UNDER IMPACTB. THIS WORK WILL BE PERFORMED IN CLOSE COLLABORATION WITH DR. CHETAN SESHADRI (UNIVERSITY OF
WASHINGTON).
€¢ PROVIDE SAMPLES FROM THE CLINICAL STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW.
SAMPLES. BLOOD AND BAL SAMPLES FROM THE POI RVRTR STUDY WILL BE ANALYZED BY
THE SUBRECIPIENT PI'S LABORATORY, BY FLOW CYTOMETRY AND CYTOF.
RESEARCH (OPTION FUNDING)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, FOR THE "OPTIONAL STUDIES €¢ PROJECT 5 RVRTR OPTION 1 SUBRECIPIENT WILL:
€¢ AS LEADER FOR PROJECT 5, RECRUIT PARTICIPANTS FORMERLY ENROLLED IN THE FIRST BCG REVACCINATION TRIAL, AND COLLECT BAL SAMPLES.
€¢ PERFORM IMMUNOLOGICAL CHARACTERIZATION ON NEW SAMPLES SUBRECIPIENT WILL COLLECT
FOR IMPACTB. 109786-5110781 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $380,524 | Mar 25, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS
CENTER (IMPAC-TB)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ELISA NEMES WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS- CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, DR. NEMES WILL:
€¢ AS LEADER FOR PROJECT 5, PERFORM IMMUNOLOGICAL CHARACTERIZATION OF REVERTERS (RVRTRS), A COHORT OF HUMANS WHO UNDERGO IGRA REVERSION EITHER SPONTANEOUSLY OR AS A RESULT OF PREVIOUS VACCINATION.
€¢ OPTIMIZE, HARMONIZE, AND APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG CELLS FROM HUMAN COHORTS RECRUITED BY PROJECTS 3-5 UNDER IMPACTB. THIS WORK WILL BE PERFORMED IN CLOSE COLLABORATION WITH DR. CHETAN SESHADRI (UNIVERSITY OF
WASHINGTON).
€¢ PROVIDE SAMPLES FROM THE CLINICAL STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW.
SAMPLES. BLOOD AND BAL SAMPLES FROM THE POI RVRTR STUDY WILL BE ANALYZED BY
THE SUBRECIPIENT PI'S LABORATORY, BY FLOW CYTOMETRY AND CYTOF.
RESEARCH (OPTION FUNDING)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, FOR THE "OPTIONAL STUDIES €¢ PROJECT 5 RVRTR OPTION 1 SUBRECIPIENT WILL:
€¢ AS LEADER FOR PROJECT 5, RECRUIT PARTICIPANTS FORMERLY ENROLLED IN THE FIRST BCG REVACCINATION TRIAL, AND COLLECT BAL SAMPLES.
€¢ PERFORM IMMUNOLOGICAL CHARACTERIZATION ON NEW SAMPLES SUBRECIPIENT WILL COLLECT
FOR IMPACTB. 109786-5110781 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $172,114 | Apr 12, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS
CENTER (IMPAC-TB)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ELISA NEMES WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS- CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, DR. NEMES WILL:
€¢ AS LEADER FOR PROJECT 5, PERFORM IMMUNOLOGICAL CHARACTERIZATION OF REVERTERS (RVRTRS), A COHORT OF HUMANS WHO UNDERGO IGRA REVERSION EITHER SPONTANEOUSLY OR AS A RESULT OF PREVIOUS VACCINATION.
€¢ OPTIMIZE, HARMONIZE, AND APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG
CELLS FROM HUMAN COHORTS RECRUITED BY PROJECTS 3-5 UNDER IMPACTB. THIS WORK WILL BE PERFORMED IN CLOSE COLLABORATION WITH DR. CHETAN SESHADRI (UNIVERSITY OF WASHINGTON).
€¢ PROVIDE SAMPLES FROM THE CLINICAL STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW.
SAMPLES. BLOOD AND BAL SAMPLES FROM THE POI RVRTR STUDY WILL BE ANALYZED BY
THE SUBRECIPIENT PI'S LABORATORY, BY FLOW CYTOMETRY AND CYTOF.
RESEARCH (OPTION FUNDING)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, FOR THE "OPTIONAL STUDIES PROJECT 5 RVRTR OPTION 1" SUBRECIPIENT WILL:
€¢ AS LEADER FOR PROJECT 5, RECRUIT PARTICIPANTS FORMERLY ENROLLED IN THE FIRST BCG REVACCINATION TRIAL, AND COLLECT BAL SAMPLES.
€¢ PERFORM IMMUNOLOGICAL CHARACTERIZATION ON NEW SAMPLES SUBRECIPIENT WILL COLLECT
FOR IMPACTB. 109786.5110781 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $0 | Mar 20, 2023 | — – — |
| Subcontractor | Agency for International Development | TO SUPPORT IM'S WORK IN SOUTH AFRICA. UCT-IM AGREEMENT Parent award context Parent award agency: Agency for International Development · Agency for International Development Parent award NAICS: 541990 Parent award performance state: DC Parent award description: IGF::CT::IGF - ADVANCING PROGRESS IN MALARIA SERVICE DELIVERY View parent award on USAspending | — | $52,073 | Feb 16, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS
CENTER (IMPAC-TB)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ELISA NEMES WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS- CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, DR. NEMES WILL:
€¢ AS LEADER FOR PROJECT 5, PERFORM IMMUNOLOGICAL CHARACTERIZATION OF REVERTERS (RVRTRS), A COHORT OF HUMANS WHO UNDERGO IGRA REVERSION EITHER SPONTANEOUSLY OR AS A RESULT OF PREVIOUS VACCINATION.
€¢ OPTIMIZE, HARMONIZE, AND APPLY MASS CYTOMETRY (CYTOF) TO CHARACTERIZE LUNG
CELLS FROM HUMAN COHORTS RECRUITED BY PROJECTS 3-5 UNDER IMPACTB. THIS WORK WILL BE PERFORMED IN CLOSE COLLABORATION WITH DR. CHETAN SESHADRI (UNIVERSITY OF WASHINGTON).
€¢ PROVIDE SAMPLES FROM THE CLINICAL STUDIES TO THE TECHNOLOGY AND MECHANISTIC CORES FOR ANALYSIS. A DETAILED LIST OF SAMPLES IS INCLUDED BELOW.
SAMPLES. BLOOD AND BAL SAMPLES FROM THE POI RVRTR STUDY WILL BE ANALYZED BY
THE SUBRECIPIENT PI'S LABORATORY, BY FLOW CYTOMETRY AND CYTOF.
RESEARCH (OPTION FUNDING)
AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM
TUBERCULOSIS (IMPACTB) CENTER, SUBRECIPIENT WILL PERFORM WORK UNDER PROJECT 5, "THE REVERTER (RVRTR) PROJECT" AS WELL AS WORK UNDER THE CROSS-CUTTING PROFILING TECHNOLOGY: CYTOF. THE PROJECT INCLUDES WORK IN THE NEMES LABORATORY AT THE SOUTH AFRICAN TUBERCULOSIS VACCINE INITIATIVE (SATVI), AN ACCREDITED UNIVERSITY OF CAPE TOWN SITE.
SPECIFICALLY, FOR THE "OPTIONAL STUDIES PROJECT 5 RVRTR OPTION 1" SUBRECIPIENT WILL:
€¢ AS LEADER FOR PROJECT 5, RECRUIT PARTICIPANTS FORMERLY ENROLLED IN THE FIRST BCG REVACCINATION TRIAL, AND COLLECT BAL SAMPLES.
€¢ PERFORM IMMUNOLOGICAL CHARACTERIZATION ON NEW SAMPLES SUBRECIPIENT WILL COLLECT
FOR IMPACTB. 109786.5110781 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: MA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $163,727 | Apr 7, 2022 | — – — |
| Subcontractor | Agency for International Development | TO SUPPORT IM'S WORK IN SOUTH AFRICA. UCT-IM AGREEMENT Parent award context Parent award agency: Agency for International Development · Agency for International Development Parent award NAICS: 541990 Parent award performance state: DC Parent award description: IGF::CT::IGF - ADVANCING PROGRESS IN MALARIA SERVICE DELIVERY View parent award on USAspending | — | $39,990 | Mar 16, 2022 | — – — |
| Subcontractor | Agency for International Development | TO SUPPORT IM'S WORK IN SOUTH AFRICA. UCT-IM AGREEMENT Parent award context Parent award agency: Agency for International Development · Agency for International Development Parent award NAICS: 541990 Parent award performance state: DC Parent award description: IGF::CT::IGF - ADVANCING PROGRESS IN MALARIA SERVICE DELIVERY View parent award on USAspending | — | $34,074 | Dec 1, 2021 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.